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CC BY-NC-ND license (http://creativeAbstract Background: Mutations in several genetic loci have been implicated in the develop-
ment of resistance to second-line anti-tuberculosis (TB) drugs (SLDs). The purpose of this study
was to investigate the prevalence of resistance to SLDs and its association with specific muta-
tions in multidrug-resistant (MDR) Mycobacterium tuberculosis clinical isolates.
Materials and methods: The study included 46 MDR-TB isolates. Mutation profiling was per-
formed by amplifying and sequencing the following six genes: gyrA/gyrB, rrs, tlyA, and
ethA/ethR, in which mutations are implicated in resistance of tubercle bacilli to ofloxacin
(OFX), amikacin (AMK), capreomycin, and ethionamide (ETH), respectively.
Results: Of the strains analyzed, 14 (30.4%) showed resistance to at least one of the four SLDs
tested. Mutations in the gyrA gene occurred in 34 (73.9%) strains, with the most common amino
acid change being Ser95Thr. The Asp94Asn and Ala90Val substitutions in the gyrA were present
exclusively in OFX-resistant strains, yet represented only 40% of all OFX-resistant strains. The
only mutation in the gyrB gene was substitution Ser447Phe, detected in one OFX-resistant
isolate. None of the AMK-resistant strains carried a mutation in the rrs gene. Mutations in
the ethA/ethR loci were found in one ETH-resistant and 11 ETH-susceptible strains.t of Applied Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw,
and.
.edu.pl (T. Jagielski).
.04.003
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440 Z. Bakuła et al.Conclusions: The results of this study challenge the usefulness of sequence analyses of tested
genes (except gyrA) for the prediction of SLD resistance patterns and highlight the need for
searching other genetic loci for detection of mutations conferring resistance to SLDs in
M. tuberculosis.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The two most detrimental forms of drug-resistant tuber-
culosis (TB) are multidrug-resistant (MDR)-TB, defined as
resistance to at least isoniazid (INH) and rifampicin (RMP),
and extensively drug-resistant (XDR)-TB, defined as MDR-TB
with additional resistance to second-line anti-TB drugs
(SLDs), that is any fluoroquinolone (FQ) and one of the
three injectable agents: amikacin (AMK), kanamycin (KAN),
or capreomycin (CAP).
Mutations in several genetic loci have been implicated in
the development of resistance to SLDs. Resistance to FQs
has been reported to be associated with mutations in two
regions known as “quinolone resistance-determining re-
gions (QRDRs)”, in the gyrA (codons 74 to 113) and gyrB
(recently proposed to span from codon 500 to codon 540)
genes, which encode the respective subunits of the DNA
topoisomerase gyrase.1,2 Resistance to KAN, AMK, and CAP
is thought to be mediated by mutations in the rrs gene,
coding for 16S rRNA.3 Furthermore, resistance to CAP has
been shown to be caused by alterations in the tlyA gene,
coding for 20-O-methyltransferase, an enzyme that meth-
ylates riboses in rRNA.4 Finally, mutations in a two-gene
operon (ethA/ethR) whose products are involved in the
activation of ethionamide (ETH) have been implicated in
conferring resistance to this drug.5
The purpose of this study was to investigate the preva-
lence of resistance to SLDs in MDR Mycobacterium tuber-
culosis clinical isolates and to search for genetic
determinants of SLD resistance.Materials and methods
The study included 46 MDR M. tuberculosis strains,
collected at the National Tuberculosis and Lung Diseases
Institute in Warsaw during the third national survey of DR-
TB. The isolates were recovered from 46 unrelated pul-
monary TB patients (40 men and 6 women; age range,
31e79 years; median age, 50.5 years) from across Poland.
These patients represented all bacteriologically-confirmed
MDR-TB cases reported in Poland in 2004 [TB cases regis-
tered (total), n Z 9493; TB notification rate, n Z 24.9/
100,000 population]. The detailed sociodemographic and
clinical characteristics of the patients whose isolates were
used in this study had been presented elsewhere.6 Primary
isolation, cultivation, and species identification were per-
formed with standard mycobacteriological methods.6 Drug
susceptibility testing was carried out using the 1% propor-
tion method on the Lo¨wenstein-Jensen medium. The cutoffdrug concentrations were as follows: INH, 0.2 mg/mL; RMP,
40 mg/mL; streptomycin (SM), 4 mg/mL; ethambutol,
2 mg/mL; ofloxacin (OFX), 2 mg/mL; AMK, 4 mg/mL; CAP,
40 mg/mL, and ETH, 40 mg/mL. Genomic DNA was extracted
using the cetyltrimethylammonium bromide method, as
previously described.7 The presence of mutations possibly
associated with resistance to SLDs was determined by
amplifying and sequencing six genetic loci, i.e., two hot-
spot targeted regions: gyrA (codons 17 to 213) and gyrB
(codons 377 to 612) and the following genes: rrs (AMK), tlyA
(CAP), and ethA/ethR (ETH). All primers used for amplifi-
cation were newly designed (Table 1). Amplification re-
actions were performed according to manufacturer’s
specific recommendations (TopTaq DNA polymerase, QIA-
GEN, Hilden, Germany). Purified polymerase chain reaction
amplicons were sequenced in both directions using the
same primers as for polymerase chain reaction amplifica-
tion and when needed, additional sequencing primers. All
alignments were done against the genome sequence of the
M. tuberculosis reference strain H37Rv (http://www.ncbi.
nlm.nih.gov/genbank/; GenBank accession number:
AL123456.3) using the BLASTN algorithm (http://blast.ncbi.
nlm.nih.gov/).
Results
A total of 14 (30.4%; 14/46) strains were resistant to at least
one of the four SLDs tested. Nine (19.5%) strains were
resistant to either OFX (7; 15.2%) or AMK (2; 4.3%), and thus
met the definition of pre-XDR-TB, whereas three (6.5%)
strains were resistant to OFX and AMK (2; 4.3%) or CAP (1;
2.2%) simultaneously and were categorized as XDR-TB
strains. Four (8.7%) strains, including two pre-XDR strains,
were resistant to ETH. The overall frequencies of resistance
to SLDs were as follows: 21.7% (n Z 10) for OFX, 8.7%
(nZ 4) for AMK, 8.7% (nZ 4) for ETH, 2.2% (nZ 1) for CAP.
Distribution of mutations and percentage of strains
carrying mutations in each of the investigated genes among
46 M. tuberculosis strains are shown in Figure 1. Non-
synonymous amino acid changes in the gyrA/gyrB loci,
excluding Ser95Thr (gyrA), which is known as natural
polymorphism8,9 occurred in seven (15.2%; 7/46) strains, six
of which were resistant to OFX. However, only five (out of
10) OFX-resistant strains contained mutations specific for
resistance to this FQ. These were Ala90Val, Asp94Asn, and
Asp94Gly in gyrA locus (four strains) and Ser447Phe in gyrB
locus (one strain). None of the four AMK-resistant strains
carried mutations in the rrs gene. The rrs mutations, in two
highly mutable regions known as the 530 and 912 loops,
were found in seven (15.2%; 7/46) strains susceptible to
Table 1 Oligonucleotide primers used for amplification of the genes analyzed.
Locus Primera Annealing temperature (C) Amplicon size (bp)
Designation Nucleotide sequence (50/30)
gyrA Fw: gyrAF ACCGGTTGACATCGAGCAGGAG 59 592
Rev: gyrAR CTCTTCGTCGGCGTCGTGATTC
gyrB Fw: gyrBF GCAACACCGAGGTCAAATC 51 710
Rev: gyrBR ACCCTTGTACCGCTGAATG
rrs Fw: rrsF TGGCCATGCTCTTGATGC 54 1707
Rev: rrsR CGCCCACTACAGACAAGAAC
rrs-seqFb TTTACGGCGTGGACTACC
rrs-seqRb CAGTAACTGACGCTGAGGAG
tlyA Fw: tlyAF TCTCTGGCCGAACTCGAAGG 58 941
Rev: tlyAR GTGTGGACGACCAGCAGAAC
ethA Fw: ethAF GCCTCGACATTACGTTGATAGC 55 1551
Rev:ethA CATCATCGTCGTCTGACTATGG
ethR Fw: ethRF AGGCCGTCAACGAGATGTC 54 750
Rev: ethRR CATGCCGCTTTGGCACTGAG
a Fw and Rev stand for forward and reverse primers, respectively. All primers used for amplification were also used for sequencing.
b Indicates additional intragenic starters used for sequencing.
Mutations for second-line anti-TB drug resistance 441AMK yet resistant to SM. All MDR-TB strains tested,
including one CAP-resistant strain, had tlyA G33A (Leu11-
Leu) polymorphism. Mutations in the ethA gene were
detected in one (out of 4) ETH-resistant strain (frameshift
mutation 1394delT; this mutation was also found in one
ETH-susceptible strain) and 10 ETH-susceptible strains.
Only one mutation (T507C; His169His) was found in the ethR
gene of a single ETH-susceptible strain.Discussion
This study is the first such extensive analysis on the genetic
determinants of SLD resistance in M. tuberculosis strains
from Poland. It is also among very few reports on the mo-
lecular mechanisms of resistance of tubercle bacilli to SLDs.
According to a recently published World Health Organiza-
tion report, a total of 32% of MDR-TB patients excreted
bacilli resistant to an FQ, a second-line injectable agent, or
both. The average proportion of MDR-TB cases with XDR-TB
was calculated at 9.6%.10 We found these two indicators at
26.1% and 6.5%, respectively.
The prevalence of mutations in gyrA and/or gyrB loci
among FQ-resistant M. tuberculosis strains is usually high
and may exceed 90%. Point mutations at codons 90, 91, and
94 in gyrA are most commonly observed.11,12 A systematic
review by Mauri et al13 showed mutations in these three
codons to account for 54% of FQ-resistant strains. In the
present study, the gyrA mutations specific for FQ resistance
(Ala90Val, Asp94Asn, and Asp94Gly) were demonstrated in
40% (4/10) of OFX-resistant strains. Another OFX-resistant
strain had a gyrB mutation (Ser447Phe). This mutation,
however, had previously been found in OFX-susceptible
strains and thus seems to be irrelevant to FQ resistance.14
Similarly, the Asp89Gly mutation in the gyrA, found here
in one OFX-resistant and one OFX-susceptible strain, had
previously been described in both OFX-resistant and -sus-
ceptible strains.12,15The A1401G substitution in the rrs gene is considered a
highly specific predictor for AMK resistance, having been
observed in close to 80% of AMK-resistant strains and never
in AMK-susceptible strains.16 Surprisingly, this mutation was
absent in our four AMK-resistant strains. The only rrs mu-
tations detected were within the 530 and 912 loops and
involved SM-resistant strains. The genetic determinants of
resistance to SM, within the sample studied, were investi-
gated in our previous report.17 These mutations were also
described in other studies and occurred in M. tuberculosis
strains resistant to SM, with or without additional resis-
tance to other aminoglycosides, including AMK. This
observation supports previous findings that mutations in the
530 and 912 regions of the rrs gene are associated with
resistance to SM but not AMK or other aminoglycosides.17e19
The only commercially available molecular diagnostic
assay to detect resistance of tubercle bacilli to SLDs,
GenoTypeMTBDRsl (Hain Lifescience, Nehren, Germany),
harbors mutations at codons 90, 91, and 94 of the gyrA gene
and mutations at 1401, 1402, and 1484 nucleotide positions
of the rrs gene as markers predictive of resistance to FQs
and aminoglycosides, accordingly. Based on the results
presented here, this test would fail to disclose 60% of
strains resistant to OFX and all strains resistant to AMK.
The association of mutations in the tlyA gene with
resistance to CAP was first inferred from an in vitro study.4
Generally, CAP-resistance-related tlyA mutations are rare
(found in up to 3% of CAP-resistant strains). A GT insertion
at position 755 has been reported most frequently and only
in CAP-resistant strains.16 Here, the only tlyA mutation,
found across the whole sample, was a synonymous transi-
tion G33A (Leu11Leu). This mutation has recently been
described by Engstro¨m et al19 in the pan-susceptible
reference strains H37Rv and H37Ra, and the in vitro
selected CAP, AMK, and KAN-resistant mutants derived from
them. Apart from the tlyA gene, the only other locus
evaluated in the context of CAP-resistance has been the
promoter region of the eis gene, coding for an amino-
glycoside acetyltransferase. However, since mutations at
Figure 1. (A) Distribution of mutations in the investigated genes among 46 Mycobacterium tuberculosis strains tested. The total
number of gene mutations in particular strains is given on the right side of the chart; (B) graph illustrating the percentage of strains
carrying mutations in the investigated genes versus the percentage of strains with wt alleles of these genes.
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CAP-resistant strains,16,20 we decided not to perform the
sequence analysis of the eis promoter in our study. It seems
that genetic markers of CAP resistance have not yet been
uncovered.
While the ability of EthA and EthR to activate ETH has
been described in previous studies, limited data exist on
the presence of ethA and ethR mutations in M. tuberculosis
clinical isolates.21 We found six mutation types in the ethA
gene in 23.9% of the strains under the study and none of
them had previously been described. This is in line with a
high degree of genetic diversity within the ethA gene in M.
tuberculosis, as evidenced in past studies. For example,
Leung et al22 detected 52 different mutation types among
63 M. tuberculosis strains (52 ETH-resistant and 11 ETH-susceptible) with an altered ethA gene. In this study, only
one out of four ETH-resistant strains contained a mutation
in the ethA/ethR locus. Previously, the prevalence of mu-
tations in the ethA/ethR operon has been estimated to
range from 37% to 100%.5,23,24 According to the literature,
the only mutations in the ethR gene consistently related to
ETH-resistance are Ala95Thr and Phe110Leu.5 These were
both undetected in our sample.Conclusion
In conclusion, the prevalence of mutations in tested loci
was similar to those described in the literature. An excep-
tion was the lack of A1401G substitution in the rrs gene,
Mutations for second-line anti-TB drug resistance 443probably due to a limited number of AMK-resistant strains in
the sample studied. Apart from two gyrA mutations (at
codons 90 and 94), none of the other changes detected in
all six genes tested could be associated with resistance to
SLDs. This casts doubt over the usefulness of sequence
analyses of tested genes (except QRDR of gyrA) for the
prediction of SLD resistance patterns and highlights the
need for searching other genetic loci for detection of mu-
tations conferring resistance to SLDs.
Nucleotide sequence accession numbers
The nucleotide sequences determined in this study were
deposited in the GenBank database (http://www.ncbi.nlm.
nih.gov/genbank/) under the following accession numbers:
KJ872562 KJ872567 for the gyrA mutants; KJ921741 and
KJ921742 e gyrB; KF796660 eKF796662 and KF796665 e rrs;
KJ872561 e tlyA; KJ872554-KJ872559 e ethA; KJ872560 e
ethR.
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